Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Assets (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Return on Assets for 12 consecutive years, with 0.91% as the latest value for Q4 2025.

  • Quarterly Return on Assets rose 39.0% to 0.91% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.91% through Dec 2025, up 39.0% year-over-year, with the annual reading at 0.99% for FY2025, 54.0% up from the prior year.
  • Return on Assets hit 0.91% in Q4 2025 for Coherus Oncology, up from 0.71% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.91% in Q4 2025 to a low of 0.61% in Q1 2023.
  • Historically, Return on Assets has averaged 0.06% across 5 years, with a median of 0.27% in 2021.
  • Biggest five-year swings in Return on Assets: crashed -56bps in 2021 and later skyrocketed 91bps in 2024.
  • Year by year, Return on Assets stood at 0.4% in 2021, then plummeted by -40bps to 0.57% in 2022, then surged by 31bps to 0.39% in 2023, then soared by 231bps to 0.51% in 2024, then surged by 76bps to 0.91% in 2025.
  • Business Quant data shows Return on Assets for CHRS at 0.91% in Q4 2025, 0.71% in Q3 2025, and 0.9% in Q2 2025.